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The	interferon	inducible	isoform	of	NCOA7	inhibits	endosome-mediated	1	
viral	entry.		2	
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Interferons	 (IFNs)	 mediate	 cellular	 defence	 against	 viral	 pathogens	 by	24	
upregulation	 of	 interferon-stimulated	 genes	 (ISGs)	 whose	 products	25	
interact	 with	 viral	 components	 or	 alter	 cellular	 physiology	 to	 suppress	26	
viral	 replication	 (1-3).	 	Among	 the	 ISGs	 that	 can	 inhibit	 influenza	A	virus	27	
(IAV)	(4)	are	the	myxovirus	resistance	1	(MX1)	GTPase	(5)	and	IFN-induced	28	
transmembrane	protein	3	(IFITM3)	(6,	7).		Here	we	use	ectopic	expression	29	
and	gene	knock-out	to	demonstrate	that	the	IFN-inducible	219	amino	acid	30	
short	 isoform	 of	 human	 nuclear	 receptor	 coactivator	 7	 (NCOA7)	 is	 an	31	
inhibitor	of	IAV	as	well	as	other	viruses	that	enter	the	cell	by	endocytosis,	32	
including	 hepatitis	 C	 virus	 (HCV).	 NCOA7	 interacts	 with	 the	 vacuolar	 H+-33	
ATPase	 (V-ATPase)	 and	 its	 expression	 promotes	 cytoplasmic	 vesicle	34	
acidification,	 lysosomal	 protease	 activity	 and	 the	 degradation	 of	35	
endocytosed	 antigen.	 	 Step-wise	 dissection	 of	 the	 IAV	 entry	 pathway	36	
demonstrates	 that	 NCOA7	 inhibits	 fusion	 of	 the	 viral	 and	 endosomal	37	
membranes	 and	 subsequent	 nuclear	 translocation	 of	 viral	38	
ribonucleoproteins	(vRNPs).	 	NCOA7,	therefore,	provides	a	mechanism	for	39	
immune	regulation	of	endo-lysosomal	physiology	that	not	only	suppresses	40	
viral	 entry	 into	 the	 cytosol	 from	 this	 compartment	but	may	also	 regulate	41	
other	 V-ATPase-associated	 cellular	 processes	 such	 as	 physiological	42	
adjustments	 to	 nutritional	 status,	 or	 the	 maturation	 and	 function	 of	43	
antigen	presenting	cells.		 	44	
Previously	we	characterized	a	panel	of	primary	and	immortalized	cells	for	IFNa-45	 inducible	resistance	to	human	immunodeficiency	virus	type-1	(HIV-1)	 infection	46	 as	the	basis	for	the	transcriptomic-led	identification	of	ISGs	that	suppress	virus	47	 infection	 (8,	9).	 	Among	 the	 cDNAs	of	 interest,	 the	 IFN-inducible	 short	 isoform	48	 (isoform	 4)	 of	 NCOA7	 (also	 termed	 NCOA7-Alternative-Start	 (AS)	 (10))	 was	49	 cloned	 into	 pEasiLV-MCS,	 a	 doxycycline-inducible,	 E2	 crimson	 expressing	50	 lentiviral	vector	(9),	and	evaluated	for	anti-retroviral	activity.	51	
	52	 HIV-1	 susceptible	U87MG	CD4+	 CXCR4+	 cultures	were	 transduced	with	NCOA7	53	 expressing	 EasiLV	 or	 a	 negative	 control	 vector.	 	 Cells	 were	 challenged	 with	 a	54	 vesicular	 stomatitis	 virus	 G-glycoprotein	 (VSV-G)-pseudotyped	 HIV-1	 derived	55	 lentiviral	 vector	 that	 expresses	GFP	 (11).	48	hr	 later,	E2	 crimson-positive	 cells	56	 were	gated	and	the	percentage	of	 infected	cells	enumerated	by	flow	cytometry.		57	 At	multiple	viral	doses,	NCOA7	expression	decreased	virus	 infectivity	 (Fig.	1a),	58	 with	similar	effects	seen	with	VSV-G	pseudotyped	vectors	derived	from	diverse	59	 retroviruses,	 including	 simian	 immunodeficiency	 virus	 (SIV),	 equine	 infectious	60	 anaemia	virus	 (EIAV)	and	 feline	 immunodeficiency	virus	 (FIV)	 (Supplementary	61	 Fig.	1a).		In	contrast,	in	challenges	with	HIV-1/Nef-internal	ribosome	entry	signal	62	 (IRES)-GFP	 carrying	 its	 natural	 envelope	 glycoprotein	 (Env),	 NCOA7	 displayed	63	 no	discernable	anti-viral	activity	(Fig.	1a).	 	We	surmised	that	 the	differences	 in	64	 NCOA7	sensitivity	between	HIV-1	particles	carrying	HIV-1	Env	or	VSV-G	could	be	65	 dictated	 by	 the	 viral	 entry	 pathway:	 HIV-1	 is	 believed	 to	 mediate	 pH	66	 independent	 membrane	 fusion	 (12)	 whereas	 VSV-G	 undergoes	 pH	 dependent	67	 fusion	 in	 early	 endosomes	 (13).	 	 We	 therefore	 extended	 this	 pseudotyping	68	 analysis	to	additional	viral	envelope	glycoproteins;	the	rabies	virus	glycoprotein	69	
(RABV-G)	mediates	entry	via	endosomes	whereas	amphotropic	murine	leukemia	70	 virus	 (MLV)	 and	 the	 feline	 endogenous	 retrovirus,	 RD114,	 Env	 are	 thought	 to	71	 facilitate	 pH	 independent	 membrane	 fusion.	 NCOA7	 inhibited	 infection	 by	72	 pseudotypes	carrying	RABV-G	but	not	amphotropic	MLV	or	RD114	Env	(Fig.	1b),	73	 consistent	with	suppressed	entry	from	the	endocytic	pathway.	74	 	75	 We	next	 tested	 the	effect	of	NCOA7	on	 two	replication	competent	viruses	 from	76	 diverse	 families	 that	 naturally	 enter	 by	 endocytic	 uptake,	 namely	 IAV	 (an	77	 orthomyxovirus)	 and	 HCV	 (a	 flavivirus).	 	 A549	 cells	 transduced	 with	 a	78	 constitutively	 expressing	 NCOA7	 lentiviral	 vector,	 or	 control	 cells,	 were	79	 challenged	with	IAV,	fixed	at	5	hr	and	stained	with	an	antibody	specific	for	viral	80	 NP,	 a	 viral	 protein	 that	 accumulates	 to	 high	 levels	 in	 the	 nucleus	 during	81	 productive	 viral	 replication	 following	 de	 novo	 expression.	 	 NCOA7	 expression	82	 reduced	the	number	of	cells	with	nuclear	NP	staining	by	~6-fold	(Fig.	1,	c	and	d);	83	 similarly,	 an	 engineered	 IAV	 expressing	NanoLuc	 luciferase	was	 also	 inhibited	84	 across	a	range	of	viral	doses	(Supplementary	Fig.	1b).		The	suppressive	effects	of	85	 NCOA7	were	most	evident	at	earlier	time-points,	as	 illustrated	by	IAV	infection	86	 of	 control	 versus	NCOA7	 expressing	 293T	 cultures	 and	 time-lapse	microscopy	87	 (Supplementary	Movie	1).	 	For	HCV	infection,	Huh-7.5	cell	cultures	were	stably	88	 transduced	with	an	NCOA7	expressing	(or	control)	 lentiviral	vector,	challenged	89	 with	 HCV	 and	 harvested	 and	 stained	 with	 an	 anti-NS5A	 antibody	 at	 48	 hr:	90	 NCOA7	expression	resulted	in	a	~50%	decrease	in	HCV	infection	(Fig.	1e).		91	 	92	 Having	 demonstrated	 that	 provision	 of	 NCOA7	 was	 sufficient	 to	 inhibit	 IAV	93	 infection,	 we	 complemented	 this	 approach	 by	 assessing	 the	 contribution	 of	94	
endogenous	NCOA7	to	the	IFNa	induced	suppression	of	IAV	infection.		We	used	95	 CRISPR/Cas9-mediated	 genome	 editing	 and	 guide	 RNAs	 targeting	 the	 unique	96	 region	 of	 the	 short	 isoform	 to	 generate	 A549	 cell	 populations	 (Fig.	 1f	 and	 1g,	97	 Supplementary	Fig.	2a)	and	clones	(Supplementary	Fig.	2b,	2c,	2d	and	2e)	lacking	98	 this	 isoform.	 	 All	 cultures	 in	 which	 the	 short	 isoform	 had	 been	 inactivated	99	 displayed	diminished	IFNa-induced	suppression	of	IAV	relative	to	control	cells.	100	 We	 additionally	 created	 matching	 cell	 populations	 in	 which	 the	 integral	101	 membrane	 protein	 IFITM3	 (6)	was	 knocked-out	 alone	 or	 in	 combination	with	102	 NCOA7	 (Fig.	 1f	 and	1g).	 	 Reductions	 in	 IFNa-mediated	 inhibition	were	 seen	 in	103	 cells	 that	 expressed	or	 lacked	NCOA7	 in	 the	 context	 of	 IFITM3	knock-out	 (~6-104	 fold	 inhibition	 in	 single	 IFITM3	 knock-out	 versus	 2.7-fold	 inhibition	 in	105	 IFITM3/NCOA7	double	knock-out),	indicating	that	the	anti-viral	effects	of	NCOA7	106	 and	IFITM3	are	cumulative	as	well	as	independent.			107	 	108	 To	 verify	 further	 that	 NCOA7	 and	 IFITM3	 inhibit	 IAV	 independently	 of	 each	109	 other,	we	showed	(using	knock-out	clonal	lines)	that	NCOA7	mediated	inhibition	110	 of	 infection	 is	 unaffected	 by	 IFITM3	 knock-out	 and	 vice	 versa	 (Supplementary	111	 Fig	3a,	3b,	and	3c).		Reintroduction	of	codon-optimized	NCOA7	isoform	4,	which	112	 can’t	 be	 targeted	 by	 our	 guide	 RNAs,	 into	 NCOA7	 knock-out	 cell	 lines	113	 reconstituted	the	full	 IFNa-mediated	inhibition	of	 IAV	(Supplementary	Fig.	3d).	114	 Together,	these	findings	confirm	that	NCOA7	is	a	significant	component	of	IFNa-115	 induced	protection	against	IAV	infection.		116	 	117	 We	next	employed	a	series	of	sequential	imaging	flow	cytometry-based	assays	to	118	 dissect	the	step(s)	in	IAV	infection	that	is	inhibited	by	NCOA7	(Fig.	2a)	(14,	15).			119	
First,	 using	 A549	 cells	 expressing	 NCOA7	 or	 a	 negative	 control	 (CD8),	 we	120	 quantified	 low	pH-induced	conformational	changes	 in	HA	at	1	hr	post-infection	121	 using	monoclonal	 antibody	 A1,	 which	 specifically	 recognizes	 acidified	 HA	 (14,	122	 16).		HA	acidification	was	not	compromised	in	the	presence	of	NCOA7	(Fig.	2b).		123	 Second,	to	study	viral	membrane	fusion	we	labelled	IAV	particles	with	the	self-124	 quenching	dye	SP-DiOC18.		Fluorescence	dequenching	of	SP-DiOC18	occurs	upon	125	 viral-endosome	 membrane	 fusion	 (reported	 to	 occur	 at	 pH<5	 for	126	 A/Victoria/3/75	 and	 ~pH	 5.5	 for	 A/Eng/195/2009	 (17,	 18))	 and	 there	 was	127	 ~50%	 decrease	 in	 the	 proportion	 of	 cells	 exhibiting	 high	 numbers	 of	 fusion	128	 events	 in	 the	presence	 of	NCOA7	 (defined	by	 the	upper	quintile	 of	 the	 control	129	 population)	(Fig.	2c)	(14).		NCOA7’s	ability	to	inhibit	viral-endosome	membrane	130	 fusion	 was	 independently	 demonstrated	 by	 challenging	 U87MG	 CD4+	 CXCR4+	131	 cells	expressing	NCOA7	(or	a	control)	with	VSV-G	pseudotyped	HIV-1	containing	132	 a	b-lactamase/Vpr	fusion	protein	that	induces	the	cleavage	of	CCF2-AM	dye	upon	133	 viral	entry	into	the	cytosol.	After	 loading	cells	with	CCF2-AM	dye,	cleavage	was	134	 analyzed	 by	 flow	 cytometry,	 showing	 that	 cytosolic	 entry	 was	 consistently	135	 reduced	 in	NCOA7	 expressing	 cells	 (Supplementary	 Fig	 4(a	 and	 b)).	 	 Third,	 to	136	 examine	the	nuclear	import	of	incoming	virion	RNPs,	we	infected	A549	cells	with	137	 IAV	 at	 high	MOI	 in	 the	 presence	 of	 cycloheximide	 (to	 prevent	de	novo	 protein	138	 synthesis),	and	quantified	nuclear	NP	staining	at	5	hr.	Consistent	with	the	fusion	139	 assays,	 NCOA7	 expression	 resulted	 in	 ~60%	 decrease	 in	 the	 number	 of	 cells	140	 exhibiting	a	high	level	of	NP	import	(defined	by	the	control	upper	quintile)	(Fig.	141	 2d).	Supplementary	Fig.	4c	confirms	this	result	by	confocal	microscopy.		In	sum,	142	 our	 mapping	 strategy	 indicated	 that	 NCOA7	 inhibits	 viral	 membrane	 fusion,	143	
whereas	 neither	 HA	 acidification	 nor	 viral	 uptake	 into	 the	 endocytic	 pathway	144	 (Supplementary	Fig.	4d)	were	compromised.		145	 	146	 NCOA7	 was	 first	 identified	 as	 an	 oestrogen	 receptor-associated	 protein	 that	147	 localizes	to	the	nucleus	upon	oestradiol	treatment	(19,	20).		It	is	thought	to	have	148	 arisen	 from	 gene	 duplication	 of	 its	 homologue,	 OXR1,	 with	 which	 it	 shares	149	 oxidation	 resistance	 properties	 (20).	 	 The	 short	 isoform	 of	 NCOA7,	 studied	150	 herein,	 has	 a	 unique	 amino-terminal	 region	 of	 25	 amino	 acids	 and	 otherwise	151	 contains	 the	 carboxy-terminal	 five	 exons	 of	 the	 longest	 isoform	 (10).	 	 The	152	 carboxy-terminal	 region	of	OXR/NCOA7	 comprises	 a	TLDc	 (TBC/LysM	Domain	153	 containing)	domain,	 the	 function	of	which	 is	currently	not	understood	(20).	 	 In	154	 contrast	to	the	longer	isoforms,	the	short	 isoform	displays	cytoplasmic	staining	155	 upon	 stable	 expression	 (Supplementary	 	 Fig.	 5a)	 with	 no	 observable	 co-156	 localization	 or	 accumulation	 with	 markers	 of	 early/late	 endosomes	157	 (Supplementary		Fig.	5	a),	and	is	the	only	isoform	that	is	IFN-inducible	(and	LPS-158	 inducible)	(10),	a	property	presumably	conferred	by	the	canonical	IFN-sensitive	159	 response	element	sequence	located	upstream	of	its	unique	amino-terminal	exon	160	 (Supplementary		Fig.	5b)	(10).			161	 	162	 Prior	 proteomic	 analyses	 of	 the	 V-ATPase	 have	 reported	 interactions	 between	163	 the	 ATP6V1B1	 subunit	 (a	 component	 of	 the	 catalytic	motor)	 and	 both	NCOA7	164	 and	 OXR1	 (21,	 22),	 consistent	 with	 activity	 as	 potential	 V-ATPase	 regulators	165	 (23).			ATP6V1B1	is	the	B-subunit	that	is	expressed	primarily	in	kidney	cells	and	166	 in	 cells	 of	 the	 inner	 ear,	whereas	ATP6V1B2	 is	 expressed	 in	non-renal	 tissues.	167	 Because	 NCOA7	 disrupts	 endosome-mediated	 virus	 entry,	 we	 used	 co-168	
immunoprecipitation	 to	 assess	 whether	 NCOA7	 associates	 with	 ATP6V1B2.		169	 Flag-tagged	NCOA7	 (or	E2-crimson)	was	 expressed	 in	U87MG	 cells,	 and	whole	170	 cell	lysates	subjected	to	anti-Flag	immunoprecipitation,	followed	by	immunoblot	171	 analysis	using	an	ATP6V1B2-specific	antibody.		As	shown	in	Fig.	3a,	interactions	172	 between	 the	short	 isoform	of	NCOA7	and	ATP6V1B2,	as	well	 as	multiple	other	173	 subunits	of	the	V-ATPase,	were	readily	detected.	174	 	175	 We	next	used	cell-based	assays	of	V-ATPase	function	to	seek	evidence	of	NCOA7-176	 mediated	up-regulation.		The	effect	of	NCOA7	on	cytoplasmic	vesicle	acidification	177	 was	 examined	 using	 LysoSensor	 Green	 DND-189	 dye,	 the	 fluorescence	178	 dequenching	of	which	is	pH	dependent	(pKa	5.2).		Living	cells	were	treated	for	1	179	 hr	 prior	 to	 visualization,	 with	 NCOA7	 expression	 markedly	 increasing	 the	180	 number	 of	 LysoSensor	 Green-positive	 punctae	 (Fig.	 3c),	 as	 well	 as	 the	181	 fluorescence	 intensity	 in	 individual	 vesicles	 (Fig.	 3b).	 	 Ratiometric	 pH	 analysis	182	 using	Lysosensor	Yellow/Blue	demonstrated	that	this	was	at	least	partly	due	to	183	 true	decreases	 in	vesicular	pH	(Fig	3c).	These	observations	are	consistent	with	184	 NCOA7	 promoting	 increased	 vesicular	 acidification	 through	 a	 regulatory	185	 interaction	with	the	V-ATPase.			186	 	187	 Regulation	 of	 the	 V-ATPase	 has	 been	 well	 described	 in	 the	 context	 of	 LPS-188	 induced	 maturation	 of	 dendritic	 cells,	 where	 increased	 acidification	 results	 in	189	 increased	 antigen	 degradation	 in	 the	 lysosome	 and	 increased	 antigen	190	 presentation	on	MHC	Class	 II	 (24,	 25).	 To	 examine	 the	 effects	 of	NCOA7	on	V-191	 ATPase	dependent	lysosomal	activation	we	quantified	the	degradative	activity	of	192	 three	different	lysosomal	cysteine	proteases,	cathepsins	B,	L	and	K,	using	Magic	193	
Red	assays	which	employ	cathepsin-specific	target	peptide	sequences	coupled	to	194	 a	fluorophore	that	is	activated	upon	peptide	cleavage	(thought	to	occur	primarily	195	 within	 endolysosomes	 (26)).	 	 As	 shown	 in	 Fig.	 3d,	 the	 degradative	 activity	 of	196	 each	cathepsin	was	substantially	increased	by	NCOA7	expression.	To	verify	that	197	 NCOA7	 increases	 the	 degradation	 of	 endocytosed	 antigen	 (as	 opposed	 to	198	 membrane	permeable	substrates),	we	measured	the	degradation	rate	of	BODIPY	199	 dye	 conjugated	 ovalbumin	 (DQ-Ovalbumin)	 by	 flow	 cytometry	 in	 NCOA7	200	 expressing	and	control	cells	 (controlling	 for	any	difference	 in	endocytic	uptake	201	 with	Alexa-647	conjugated	ovalbumin).	Fig.	3e	shows	that	NCOA7	promotes	the	202	 degradation	 of	 Ova	 DQ	 demonstrating	 that	 the	 increase	 in	 acid-dependent	203	 lysosomal	protease	activity	enhances	the	degradation	of	material	entering	cells	204	 by	endocytosis,	further	supporting	the	assertion	that	NCOA7	promotes	V-ATPase	205	 activity.		206	 	207	 Here	we	 identify	 the	 short	 isoform	 of	 human	 NCOA7	 (isoform	 4)	 as	 an	 IFNa-208	 inducible	inhibitor	of	viruses	entering	the	cell	by	endocytosis.	 	NCOA7	interacts	209	 with	 the	 V-ATPase	 and	 stimulates	 vesicle	 acidification,	 lysosomal	 protease	210	 activity	 and	 the	 degradation	 of	 endocytosed	 material.	 	 These	 perturbations	211	 compromise	the	fusion	capabilities	of	viruses	that	are	adapted	to	the	dynamics	of	212	 the	 endo-lysosomal	 pathway,	 thereby	 inhibiting	 infection.	 	 The	 endocytic	213	 pathway	is	also	important	for	the	entry	of	many	bacterial	pathogens	and	toxins	214	 and	a	role	for	OXR1/NCOA7	homologues	has	been	suggested	in	protection	from	215	
Vibrio	 cholera	 infection	 in	Drosophila	 models	 (27).	 	 These	 findings	 add	 innate	216	 immunity	 to	 the	growing	number	of	biological	contexts	 for	which	regulation	of	217	 the	 V-ATPase	 is	 a	 focus	 of	 investigation:	 for	 instance,	 cellular	 nutrition,	 the	218	
pathology	 of	 neurodegeneration,	 adaptive	 immunity	 and	 the	 growth	 of	219	 transformed	 cells	 (24,	 28,	 29).	 Finally,	 in	 addition	 to	 providing	 important	220	 insights	 into	 the	 antiviral	 action	 of	 IFN,	 the	 identification	 of	 this	 cytokine-221	 responsive	mechanism	 for	 regulating	 the	endo-lysosomal	 system	may	 facilitate	222	 therapeutic	 manipulation	 of	 disease	 processes	 that	 stem	 from	 V-ATPase-223	 associated	endo-lysosomal	dysfunction.	224	 	225	
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Materials	and	Methods:	268	
Plasmids	and	constructs	269	 The	 EasiLV	 system	 including	 pEasiLV-MCS	 and	 pEasiLV-CD8-Flag	 (negative	270	 control)	 has	 been	 described,	 as	 has	 the	 lentiviral	 vector	 system	 employing	271	 pRRL.sin.cPPT.CMV/IRES-puro.WPRE	used	for	the	generation	of	cell	lines	stably	272	 expressing	genes	of	interest	(9).	The	CMV	promoter	from	the	latter	system	was	273	 replaced	 with	 SFFV	 promoter	 (amplified	 from	 HR	 SIN	 CSGW,	 a	 gift	 from	 Paul	274	 Lehner,	 and	 cloned	 using	 ClaI/BamHI)	 to	 yield	 pRRL.sin.cPPT.SFFV/IRES-275	 puro.WPRE.	 NCOA7	 variant	 6	 (NM_001199622.1)	 (encoding	 isoform	 4	276	 NP_001186551.1)	 was	 amplified	 using	 the	 SuperScript®	 III	 One-Step	 RT-PCR	277	 System	with	Platinum®	Taq	(Invitrogen)	from	100	ng	RNA	obtained	from	IFNa-278	 treated	 monocyte-derived	 macrophages	 (MDMs)	 using	 primers	 5’-	279	 aaatttggatccATGAGAGGCCAAAGATTACCCTTGG-3’	 and	 5’-280	 aaatttCTCGAGTCAATCAAATGCCCACACCTCCAG-3	 (or	 the	 Flag-tagged	 5’-281	 aaatttggatccATGGACTACAAAGACGACGACAAAAGAGGCCAAAGATTACCCTTGG-282	 3’).	 A	 codon-optimized	 version	 of	 NCOA7	 (coNCOA7)	 CDS	 with	 the	 25	 first	283	 codons	 modified	 was	 synthesized	 (Eurofins;	 5’-284	 atgcgcggtcagcgtctgccactagatattcaaatcttttactgcgcgcgtcccgatgaggaaccgttcgtaaaa)	285	 and	 amplified	 by	 PCR.	 Firefly	 luciferase	 cDNA	 was	 amplified	 from	 pGL4	286	 (Promega)	and	E2-crimson	cDNA	from	pEasiLV-MCS.	The	cDNAs	were	 inserted	287	 into	 BamHI-XhoI-digested	 pRRL.sin.cPPT.CMV/IRES-puro.WPRE,	288	 pRRL.sin.cPPT.SFFV/IRES-puro.WPRE	 or	 pEasiLV-MCS.	 NL4-3/Nef-IRES-GFP	289	 and	 NL4-3/Nef-IRES-Renilla	 were	 obtained	 from	 the	 NIH	 AIDS	 Reagent	 and	290	 Reference	 Program	 (pBR43IeG,	 cat	 no.	 11349)	 and	 from	 Sumit	 Chanda,	291	 respectively.		pBlaM-Vpr	and	pAdVAntage	have	been	described	(30).	292	
HIV-1,	 FIV,	 SIV,	EIAV	based	vector	plasmids	which	 express	GFP	upon	 infection	293	 have	previously	been	described	(11,	31-34)	as	have	the	Env-encoding	constructs	294	 phCMV-MLV-A	(35),	phCMV-RD114/TR	(35)	and	pRABIES	Env	(36).			295	 In	order	 to	modify	 the	A/Victoria/3/75	polymerase	PA	gene	 for	 co-expression	296	 with	NanoLuc	 luciferase,	a	PA-NanoLuc	encoding	 fragment	 (37)	 in	which	PA	 is	297	 fused	 with	 the	 porcine	 teschovirus	 P2A	 and	 the	 NanoLuc	 luciferase	 gene	 was	298	 inserted	into	the	PasI	site	of	PolI-RT-Victoria	PA	plasmid.	The	12-plasmid	system	299	 used	 to	 rescue	 IAV	 Victoria-NanoLuc	 reporter	 virus	 was	 provided	 by	 Wendy	300	 Barclay.	 	The	firefly	luciferase	gene	from	pHSP1-Firefly	(9)	was	replaced	by	the	301	 eGFP	coding	sequence	to	generate	pHSP1-eGFP.		302	 HCV	particles	were	generated	using	the	cell	culture-adapted	clone	J6/JFH-1	(38).		303	 The	 LentiCas9-Blast	 and	 LentiGuide-Puro	 vectors	were	 a	 gift	 from	Feng	 Zhang	304	 (39)	 (Addgene).	 The	 LentiGuide-Neo	 vector	 was	 generated	 by	 replacing	 the	305	 puromycin	 resistance	 gene	 in	 LentiGuide-Puro	 with	 the	 neomycin	 resistance	306	 gene	 (amplified	 using	 PCR	 from	 pcDNA3.1+)	 and	 using	 BsiWI	 and	 MluI	 sites.	307	 Guide	 RNA	 coding	 oligonucleotides	 were	 annealed	 and	 ligated	 into	 BsmBI-308	 digested	 LentiGuide-Puro	 or	 LentiGuide-Neo	 vectors,	 as	 described	 (Addgene).	309	 The	 gRNA	 coding	 sequences	 used	 were	 as	 follow:	 g1-GFP	 5’-310	 gagctggacggcgacgtaaa,	 g1-CTRL	 5’-agcacgtaatgtccgtggat;	 g2-CTRL	 5’-311	 caatcggcgacgttttaaat;	 g-IFITM3	 5’-taggcctggaagatcagcac;	 g1-NCOA7	 5’-312	 aaaaggctcttcgtcaggtc;	 g2-NCOA7	 5’-ttcacaaaaggctcttcgtc;	 g3-NCOA7	 5’-313	 ggatgtccaagggtaatctt.	 The	 3	 NCOA7	 guides	 were	 designed	 to	 target	 the	 first	314	 coding	exon	of	NCOA7	variant	6	(NM_001199622.1),	which	is	unique	to	the	short	315	 IFN-inducible	isoform	4	(NP_001186551.1)	studied	herein.	316	 	317	
Cell	lines	318	 Human	 293T,	 U87MG	 CD4+	 CXCR4+(9),	 	 A549,	 MDCK	 and	 Huh-7.5	 cells	 were	319	 maintained	in	complete	Dulbecco's	modified	Eagle	medium	(DMEM)	(Gibco)	and	320	 THP-1	 cells	were	maintained	 in	 Roswell	 Park	Memorial	 Institute	 (RPMI)	 1640	321	 medium	 (Gibco),	 both	 supplemented	 with	 10%	 foetal	 bovine	 serum	 and	322	 penicillin/streptomycin.	Non-essential	amino	acids	were	added	for	Huh-7.5	cells.		323	 293T,	A549,	MDCK	and	THP-1	cells	were	obtained	from	American	Type	Culture	324	 Collection	 (ATCC).	 Huh-7.5	 were	 originally	 obtained	 from	 the	 Rice	 laboratory	325	 (40).	U87MG	cells	were	originally	obtained	from	the	NIH	AIDS	Reagent	Program	326	 and	modified	to	express	CD4	and	CXCR4	(9).		A549,	293T,	U87MG	CD4+	CXCR4+,	327	 and	Huh-7.5	cells	stably	expressing	NCOA7,	CD8	or	E2-crimson	were	generated	328	 by	 transduction	 with	 either	 RRL.sin.cPPT.CMV/IRES-puro.WPRE	 or	329	 RRL.sin.cPPT.SFFV/IRES-puro.WPRE	containing-vectors	(cDNA	as	indicated)	and	330	 were	maintained	under	1	µg/ml	puromycin	selection.			331	 For	 CRISPR-Cas9-mediated	 gene	 disruption,	 A549	 cells	 stably	 expressing	 Cas9	332	 were	first	generated	by	transduction	with	the	LentiCas9-Blast	vector	followed	by	333	 blasticidin	selection	at	10	µg/ml.		Cas9-expressing	A549s	were	then	transduced	334	 with	 guide	 RNA	 expressing	 LentiGuide-Puro	 and	 Lentiguide-Neo	 vectors	 and	335	 cells	selected	with	antibiotics	for	at	least	15	days.		Single	CRISPR/Cas9	knock-out	336	 cellular	 clones	 were	 isolated	 using	 a	 FACSAria	 IIu	 cell	 sorter	 (Beckton	337	 Dickinson).	338	 When	indicated,	IFNa	(INTRON®	A;	Merck	Sharp	&	Dohme	Corp.)	was	added	at	339	 1,000	U/ml	for	16-24	hr	prior	to	virus	infection.	Cells	were	treated	with	50	nM	340	 bafilomycin	A1	(an	 inhibitor	of	 the	V-ATPase)	(Sigma-Aldrich)	 for	1	hr	prior	to	341	 infection	 and	 throughout	 the	 assay	 where	 indicated;	 cycloheximide	 (Sigma-342	
Aldrich)	was	used	at	1	mM	to	prevent	de	novo	protein	synthesis	and	the	media	343	 replenished	every	2	hr	if	required.	 344	 	345	
Lentiviral	production	and	infection	346	 Lentiviral	vector	stocks	were	obtained	by	polyethylenimine	(PEI),	TransIT-2020	347	 (Mirus	 Bio	 LLC)	 or	 Lipofectamine	 3000	 (Thermo	 Scientific)-mediated	multiple	348	 transfection	of	293T	cells	 in	6-well	plates	with	vectors	expressing	Gag-Pol,	 the	349	 miniviral	 genome,	 the	 Env	 glycoprotein,	 and	 when	 required	 (i.e.	 for	 EasiLV	350	 production),	 a	 TetR-KRAB	 expression	 plasmid	 (41)	 (pptTRKrab,)	 at	 a	 ratio	 of	351	 1:1:0.25:0.5.	The	culture	medium	was	changed	6	hr	post-transfection,	and	vector	352	 containing	supernatants	harvested	36	hr	later,	filtered	and	stored	at	-80°C.		Wild	353	 type	 HIV-1	 particles	 (NL4-3/Nef-IRES-GFP,	 NL4-3/Nef-IRES-Renilla)	 were	354	 generated	 by	 polyethylenimine	 (PEI)-based	 transfection	 of	 293T	 cells.	 b-355	 lactamase-Vpr	 (BlaM-Vpr)-carrying	 viruses,	 VSV-G-pseudotyped	 or	 bearing	 the	356	 wild	 type	Env,	were	produced	by	 co-transfection	of	293T	cells	with	pMD.G	 (or	357	 not),	 the	 NL4-3/Nef-IRES-Renilla	 provirus	 expression	 vector,	 pBlaM-Vpr	 and	358	 pAdVAntage	at	a	ratio	of	(1.33:)4:1:0.5,	as	previously	described		(30).		359	 For	EasiLV-based	experiments,	U87MG	CD4+	CXCR4+	cells	were	transduced	with	360	 EasiLV	 stocks	 encoding	 genes	 of	 interest	 and	 the	 medium	 changed	 at	 6	 hr.		361	 Doxycycline	(0.4-1	µg/ml)	was	added	for	24-48	hr,	 the	cells	plated	at	2.5	x	104	362	 per	well	in	96-well	plates,	and	then	challenged	with	GFP-expressing	virus	stocks	363	 or	NL4-3.	 	The	percentage	of	 infected,	GFP-expressing	cells	was	enumerated	by	364	 flow	cytometry	48	hr	after	infection.		365	 HIV-1NL4-3	 containing,	 filtered	 supernatants	 were	 routinely	 purified	 by	366	 ultracentrifugation	 through	 a	 sucrose	 cushion	 (20%	w/v;	 75	min;	 4°C,	 28,000	367	
rpm	 using	 a	 Beckman	 Coulter	 SW	 32	 rotor),	 resuspended	 in	 DMEM	 medium	368	 without	 serum	 and	 stored	 in	 small	 aliquots	 at	 -80°C.	 Viral	 particles	 were	369	 normalized	 by	 p24Gag	 ELISA	 or	 p24Gag	 AlphaLisa	 (Perkin-Elmer)	 and/or	 by	370	 determining	their	infectious	titers	on	U87MG	cells	(for	GFP	expressing	LVs,	RVs	371	 and	HIV-1).	The	multiplicity	of	infection	(MOI)	for	LV	stocks	was	determined	by	372	 infecting	a	known	number	of	cells	with	standardized	amounts	of	viral	particles	373	 and	evaluating	by	flow	cytometry	the	percent	of	infected	cells	2-3	days	later.	For	374	 instance,	 an	MOI	 of	 0.1	would	 theoretically	 correspond	 to	 the	 volume	 of	 virus	375	 necessary	to	obtain	10%	of	GFP-expressing	cells.		376	 	377	
IAV	production	and	infection:	378	 A/Eng/195/2009	 and	 A/Victoria/3/75	 particles	 were	 provided	 by	 Wendy	379	 Barclay	 and	 amplified	 in	 MDCK	 cells	 using	 serum-free	 DMEM	 containing	 0.5	380	 µg/ml	 TPCK-treated	 trypsin	 (Sigma-Aldrich).	 	 Stocks	 were	 titred	 by	 plaque	381	 assays	on	MDCK	 cells,	 or	 on	A549	 cells	 to	determine	multiplicities	 of	 infection	382	 (MOI)	defined	by	the	proportion	of	NP-positive	nuclei	at	12	hr	post	infection.	A	383	 12-plasmid	 system	was	 used	 to	 rescue	 A/Victoria/3/75	 and	 the	 IAV	 Victoria-384	 NanoLuc	 reporter	 virus.	 The	 8	 PolI	 plasmids	 (0.5	 µg	 each)	 and	 the	 4	 rescue	385	 plasmids	(PB1,	PB2,	PA:	0.32	µg	each,	NP:	0.64	µg)	were	co-transfected	into	293T	386	 cells	 in	6-well	plates	using	Lipofectamine3000	(Thermo	Scientific).	After	24	hr,	387	 the	cells	were	removed	and	co-cultured	with	MDCK	cells	in	25	ml	flasks.	The	first	388	 8	hr	of	 co-culture	was	carried	out	 in	10%	serum,	after	which	 the	medium	was	389	 replaced	with	serum-free	medium	containing	0.5	µg/ml	of	TPCK-treated	trypsin.	390	 Supernatants	from	day	5	post-transfection	were	used	for	virus	amplification	on	391	 MDCK	cells.	392	
All	 IAV	 challenges	 were	 performed	 in	 serum-free	 DMEM	 for	 1	 hr	 (unless	393	 otherwise	 specified)	 and	 the	 medium	 was	 subsequently	 replaced	 with	 DMEM	394	 containing	 10%	 FBS	 (where	 the	 experiment	 lasted	 more	 than	 1.5	 hr).	 	 For	395	 microscopy-based	infectivity	assays,	A549	cells	stably	expressing	CD8	or	NCOA7	396	 were	plated	on	coverslips	in	12-well	plates	at	a	density	of	1	x	105	cells	per	well.	397	 The	 following	 day,	 cells	 were	 infected	 with	 A/Eng/195/2009	 (MOI	 of	 10).		398	 Fixation	was	performed	at	5	hr	post-infection	using	4%	paraformaldehyde	(PFA)	399	 in	phosphate	buffered	saline	(PBS)	for	10	min,	and	the	cells	were	permeabilized	400	 using	0.2%	Triton	X-100	for	10	min.	After	quenching	and	blocking	in	buffer	NGB	401	 (50	mM	NH4Cl,	2%	goat	serum,	2%	bovine	serum	albumin	in	PBS)	for	1	hr,	cells	402	 were	 incubated	 with	 anti-NP	 antibody	 (Hb65;	 provided	 by	 Yohei	 Yamauchi)	403	 (14),	diluted	 in	buffer	NGB	for	1	hr	and	subsequently	 incubated	with	an	Alexa-404	 488	conjugated	anti-mouse	secondary	antibody.		Cells	were	then	stained	with	1	405	
µg/ml	 4',6-diamidino-2-phenylindole	 (DAPI),	 washed,	 mounted	 on	 coverslips	406	 and	 examined	 using	 a	 Nikon	 A1	 confocal	 microscope	 (10X	 objective)	 with	407	 captured	 images	 analyzed	 using	 FIJI	 (42)	 to	 determine	 the	 percentage	 of	 GFP-408	 expressing	cells.		For	time-lapse	microscopy,	293T	cells	stably	expressing	CD8	or	409	 NCOA7	were	seeded	(5	x	104	per	well)	in	a	48-well	plate	and	transfected	with	0.1	410	
µg	pHSP1-eGFP	using	Lipofectamine	2000	(Thermo	Scientific).	pHSP1-eGFP	is	a	411	 minigenome-like	 reporter	 construct	 that	 expresses	 GFP	 and	 when	 transfected	412	 into	 target	 cells	 is	 transcribed	 by	 host	 RNA	 polymerase	 to	 produce	 a	 negative	413	 sense,	viral	genomic	like	segment	(with	5’-triphosphate	and	3’-hydroxyl).		Upon	414	 IAV	 infection,	 this	 segment	 is	 recognized	 by	 the	 viral	 RNA	 polymerase	 to	415	 generate	 GFP-expressing	 mRNA.	 	 After	 ~24	 hr,	 the	 cells	 were	 infected	 with	416	 A/Eng/195/2009	(MOI	of	1)	and	then	monitored	by	time-lapse	microscopy	with	417	
images	 acquired	 at	 20	 min	 intervals	 from	 2	 to	 ~18	 hr	 post-infection	 using	 a	418	 Nikon	Ti-Eclipse	wide-field	 inverted	microscope	(40X	objective)	and	controlled	419	 by	NIS	Elements	 software.	 	Movies	were	 created	using	FIJI	 (42).	 	The	Victoria-420	 Nanoluc	 infection	experiments	were	performed	 in	duplicate	or	 triplicate	 in	96-421	 well	 plates	with	 cultures	maintained	 for	 7	 hr	 post-challenge.	 NanoLuc	 activity	422	 was	 measured	 with	 the	 Nano-Glo	 assay	 system	 (Promega),	 and	 luminescence	423	 was	detected	using	a	plate	reader	(Infinite®	200	PRO,	Tecan).	424	
	425	
HCV	production	and	infection:	426	 Cell	culture-derived	HCV	particle	stocks	were	produced	by	electroporation	of	in	427	 vitro-transcribed	viral	RNA	into	Huh-7.5	cells	using	a	Bio-Rad	Gene	Pulser	Xcell	428	 (Bio-Rad)	(43).	A	cell	culture-adapted	J6/JFH-1	derivative	virus,	named	Clone	2,	429	 was	used	for	this	study.		Virus-containing	supernatants	were	collected	48,	72	and	430	 96	 hours	 post-electroporation	 and	 titrated	 by	 limiting	 dilution	 assay,	 as	431	 described	 (44).	 	 Transduced	 Huh-7.5	 cells	 were	 seeded	 in	 24-well	 plates,	432	 challenged	with	 virus	 (MOI	0.5)	 and	 incubated	 for	48	hr.	 Cells	were	harvested	433	 using	 AccuMax	 (eBioscience),	 fixed	 with	 4%	 PFA,	 permeabilized	 with	 PBS-434	 saponin	 (0.2%)	 and	 stained	 for	 1	 hr	 at	 room	 temperature	with	 an	 Alexa-647-435	 conjugated	 antibody	 (9E10	 clone)	 specific	 for	 the	 HCV	 non-structural	 protein	436	 NS5A	 in	 PBS-saponin	 (0.2%).	 The	 percentage	 of	 infected	 cells	 determined	 by	437	 flow	cytometry.		438	
	439	
Quantification	of	mRNA	expression			440	 3-5	 x	105	 cells	with	or	without	24hr	 treatment	with	 IFNa	were	harvested	 and	441	 total	 RNA	 was	 extracted	 using	 the	 RNeasy	 kit	 (Qiagen)	 employing	 on-column	442	
DNase	treatment.	500	ng	RNA	was	used	to	generate	cDNA,	which	was	analyzed	443	 by	qPCR	using	TaqMan	gene	 expression	 assays	 (Applied	Biosystems)	 for	ACTB	444	 (Hs99999903_m1)	 or	 GAPDH	 (Hs99999905_m1).	 	 For	 the	 short	 isoform	 of	445	
NCOA7,	 the	 primers	 used	 were	 5’-GATTACCCTTGGACATCCAGATTTTCTATT-3’	446	 and	 5’-CACCTCTTCGTCCTCGTCTTCATAGT-3’	 and	 the	 probe	 sequence	 was	 5’-447	 FAM-AGGCAAAGCGCAGGAAGAGCACATGC-TAMRA-3’.	 	 Triplicate	 reactions	were	448	 run	 according	 to	 the	 manufacturer’s	 instructions	 using	 an	 ABI	 Prism	 model	449	 7900HT	sequence	detection	platform,	and	data	was	analyzed	using	RQ	software	450	 (Applied	 Biosystems).	 GAPDH	 and	 ACTB	 mRNA	 expression	 was	 used	 to	451	 normalize	samples.		452	 	453	
T7-endonuclease	assay		454	 To	assess	CRISPR/Cas9	mediated	editing	of	the	NCOA7	and	IFITM3	loci,	genomic	455	 DNA	 was	 extracted	 from	 cell	 populations	 (DNeasy,	 Qiagen)	 and	 an	 amplicon	456	 spanning	 the	 targeted	 genomic	 region	was	 generated	 on	50	ng	DNA	by	 touch-457	 down	 PCR	 using	 the	 primers	 5’-tgctggtagaaatgtcagcacaatcctttc-3’ and 5’-458	
aaagttcattttactctaaaatccatttttggccc-3’,	 5’-tccctgatctcagggcgggg	 and	 5’-459	 aggcccgaaaccagaaggc,	 respectively. Amplicons were then subject to 460	
denaturation, reannealing and T7-endonuclease (NEB) digestion. 	461	 	462	
Indirect	imunofluorescence	463	 For	 visualization	 of	 NCOA7	 localization	 by	 confocal	 microscopy,	 U87MG	 CD4+	464	 CXCR4+	cultures	were	transduced	with	lentiviral	vectors	containing	Flag-tagged	465	 NCOA7	as	described	above	and	were	subsequently	plated	on	coverslips	treated	466	 with	 poly-L-lysin.	 Fixation,	 staining	 with	 anti-Flag	 antibody	 (Sigma-Aldrich	467	
F3165	or	F7425,	or	Miltenyi	130-101-576),	anti-EEA1	(BD	Biosciences	610457),	468	 anti-CD63	 (Santa-Cruz	 sc5275)	 and	 anti-Lamp1	 (Sigma-Aldrich	 L1418),	 and	469	 Alexa-488	 and	 Alexa-546	 conjugated	 anti-mouse	 or	 anti-rabbit	 secondary,	 and	470	 and	image	acquisition	was	performed	as	in	previous	sections	with	either	a	Zeiss	471	 LSM880	confocal	microscope.		472	 	473	
Influenza	A	virus	uptake	assay	474	 Stably	expressing	E2-crimson-	or	NCOA7-A549	cells	were	seeded	at	105	cells	and	475	 2	x	105	cells	per	well,	respectively,	in	12-well	plates.	The	following	day,	medium	476	 was	removed	and	cells	were	incubated	in	serum-free	DMEM	with	3	x	105	and	1.5	477	 x	106	PFU	of	A/Victoria/3/75	for	20	min	at	37°C.	 	A	heat-inactivated	virus	was	478	 used	at	the	highest	viral	input	as	a	negative	control.	Cells	were	then	trypsinized,	479	 washed	 and	 fixed	 in	 2%	 PFA.	 BD	 Perm/washTM	 (BD	 Biosciences)	was	 used	 to	480	 permeabilized	and	stained	the	cells	with	anti-NP	antibody	(Hb65)	and	Alexa	488	481	 secondary	 antibody	 according	 to	 the	 manufacturer’s	 instructions.	 Cells	 were	482	 analyzed	using	a	NovoCyteTM	(Ozyme)	cytometer.	483	 	484	
HA	acidification	assay	485	 A549	cells,	parental	or	stably	expressing	CD8	or	NCOA7,	were	seeded	in	6-well	486	 plates.	Unmodified	cells	were	treated	with	50	nM	bafilomycin	A1	for	1	hr	prior	to	487	 infection	(inhibition	control).	 	Medium	was	removed	and	cells	were	 infected	 in	488	 serum-free	DMEM	with	A/Victoria/3/75	at	MOI	of	30	and	incubated	for	1	hr	at	489	 37°C.	 	Cells	were	 then	 trypsinized,	 and	both	 fixed	and	 stained	using	 IntraStain	490	 (Dako)	 with	 monoclonal	 antibody	 A1	 (14),	 which	 is	 specific	 for	 HA	 that	 has	491	 undergone	 low	 pH	 induced	 conformational	 change	 (provided	 by	 Yohei	492	
Yamauchi).	Alexa-647	 conjugated	 anti-mouse	 total	 IgG	 (Life	Technologies)	was	493	 used	as	secondary	antibody,	and	cells	were	analyzed	by	imaging	flow	cytometry	494	 (see	below)	using	the	647	nm	laser	for	excitation.			495	 	496	
Membrane	fusion	assay	497	 A/Victoria/3/75	 was	 labeled	 with	 the	 self-quenching	 dye	 SP-DiOC18(3)	498	 (Molecular	Probes).	 	 SP-DiOC18(3)	was	added	 to	1	ml	of	virus	 stock	 in	 serum-499	 free	DMEM	(containing	approximately	2.5	x	107	infectious	units	per	ml)	at	a	final	500	 concentration	of	0.2	µM	in	a	screw-capped	eppendorf	tube		(45).		The	tube	was	501	 protected	 from	light,	 incubated	while	rolling	 for	1	hr	at	room	temperature	and	502	 subsequently	 stored	 at	 -80°C	 or	 used	 as	 required.	 	 For	 the	 heat	 inactivation	503	 control,	 virus	was	 kept	 at	 75°C	 for	 30	min	 and	 returned	 to	 room	 temperature	504	 prior	 to	 labelling.	 	 Labeled	 virus	 preparations	 were	 passed	 through	 a	 0.45μm	505	 filter.	 Labeled	 virus	 was	 diluted	 in	 serum	 free	 DMEM	 for	 infection	 of	 CD8	 or	506	 NCOA7	expressing	A549	monolayers	at	MOI	of	10.	Cells	were	 incubated	for	1.5	507	 hr	 after	 infection,	 harvested	 with	 trypsin,	 fixed	 with	 4%	 PFA	 for	 10	 min	 and	508	 analyzed	by	imaging	flow	cytometry	using	the	488	nm	laser	for	excitation.		509	 	510	
BlaM-VPR	assay	for	lentiviral	entry	511	 The	 BlaM-VPR	 assay	 has	 previously	 been	 described	 (30).	 Briefly,	 2	 x	 105	E2-512	 crimson	or	NCOA7-expressing	U87MG	CD4+	CXCR4+	cells	were	plated	in	24	well	513	 plates	the	day	prior	to	infection.	Cells	were	incubated	with	increasing	amounts	of	514	 VSV-G	 pseudotyped	 or	 wild-type	 Envelope,	 BlaM-VPR	 containing	 NL4-3/Nef-515	 IRES-Renilla	viruses	(31.2,	62.5	or	125	ng	p24)	or	mock	infected	for	3	hr.	Cells	516	 were	 then	 washed	 once	 in	 CO2-independent	 media	 and	 loaded	 with	 CCF2-AM	517	
substrate	(Invitrogen)	 	containing	development	media	(CO2-independent	media	518	 containing	1.6	mM	probenecid)	 for	2	hr	at	 room	 temperature	before	2	washes	519	 and	 incubation	 at	 room	 temperature	 for	 16	 hr	 in	 development	media.	 Finally,	520	 cells	were	harvested,	washed	and	fixed	in	2%	PFA,	before	analysis	with	using	a	521	 FACSCanto	II	(BD	Biosciences).		522	 	523	
Nuclear	virion	RNP	(vRNP)	import	assay:	524	 A549	 cells	 were	 plated	 and	 unmodified	 cells	 treated	 with	 bafilomycin	 A1	 as	525	 above.	 	 1	 mM	 cycloheximide	 was	 maintained	 in	 the	 medium	 throughout	 the	526	 experiment.	 Cells	 were	 infected	 with	 A/Eng/195/2009	 at	 MOI	 of	 10.	 	 The	527	 medium	was	 changed	 at	 1	 hr	 (as	 above)	 and	 again	 at	 3	 hr	 to	 ensure	 optimal	528	 cycloheximide	 activity.	 	 Cells	 were	 fixed	 in	 4%	 PFA	 at	 5	 hr,	 stained	 using	529	 Permwash	 (BD	 Biosciences)	 according	 to	 the	manufacturer’s	 instructions	with	530	 anti-NP	 (Hb65)	 antibody	 and	 secondary	 as	 above.	 	 DAPI	 staining	was	 used	 to	531	 demarcate	 the	 nucleus	 (0.1	µg/ml	 for	 5	min).	 Cells	were	 analyzed	 by	 imaging	532	 flow	cytometry	using	a	642	nm	laser	for	excitation.		For	the	parallel	visualization	533	 of	nuclear	vRNP	import	by	confocal	microscopy,	cells	were	plated	on	coverslips	534	 as	described	above,	infections	conditions	were	identical	and	staining	and	image	535	 acquisition	was	performed	as	described.				536	 	537	
Vesicle	acidification	and	cathepsin	activity	assays	538	 Transduced	 A549	 cells	 were	 plated	 in	 6-well	 plates	 and	 treated	 with	 0.1	 µM	539	 LysoSensor	 Green	 DND-189	 (Molecular	 Probes)	 for	 1	 hr,	 or	 with	 10	 µM	540	 Lysosensor	Yellow/Blue	DND-160	for	30	min	at	37°C.	 	Cells	were	subsequently	541	 trypsinized,	 washed	 and	 resuspended	 for	 immediate	 analysis	 by	 imaging	 flow	542	
cytometry.	 A	 488	 nm	 laser	 was	 used	 for	 Lysosensor	 Green.	 	 For	 Lysosensor	543	 Yellow/Blue	a	405	nm	 laser	was	used	 for	 excitation	and	 the	 ratio	of	 the	mean	544	 fluorescence	intensity	of	the	cells	in	channels	420-505	nm	and	505-570	nm	was	545	 measured	for	the	analysis.		For	analysis	by	confocal	microscopy,	A549	cells	were	546	 plated	 in	 glass-bottomed	 dishes	 and,	 the	 following	 day,	 treated	 with	 1	 µM	547	 LysoSensor	 Green	 for	 1	 hr.	 	 Living	 cells	 were	 subsequently	 washed	 and	548	 visualized	 using	 a	 Nikon	 A1R	 confocal	 microscope	 and	 a	 488	 nm	 laser.	 	 To	549	 analyze	cathepsin	B,	L	and	K	activity,	the	Magic	Red	reagents	(Immunochemistry	550	 Technologies)	 specific	 for	 each	of	 these	proteases	were	 reconstituted	 in	DMSO	551	 and	 subsequently	 diluted	 in	 distilled	 H20	 to	 form	 a	 26X	 solution	 as	 per	 the	552	 manufacturer’s	instructions.	Approximately	5	x	105	transduced	A549	cells	were	553	 trypsinized	from	a	6-well	plate	and	resuspended	in	150	µl	medium,	to	which	the	554	 reagent	was	added.	Cells	were	incubated	for	1.5	hr	at	37°C,	washed,	fixed	in	2%	555	 PFA	and	analyzed	by	imaging	flow	cytometry	using	a	561	nm	laser	for	excitation.		556	 	557	
Ovalbumin	degradation	assay	558	 CD8	 or	 NCOA7	 expressing	 cells	 were	 plated	 in	 48	 well	 plates.	 	 Cells	 were	559	 incubated	in	serum-free	media	containing	250μg/ml	of	DQ	Ovalbumin	(Ova-DQ),	560	 which	emits	fluorescence	upon	degradation,	or	Alexa	Fluor	647	Ovalbumin	(Ova-561	 647)	 for	 1	 hr	 at	 37°C	 followed	 by	 washing.	 	 Ova-647	 containing	 cells	 were	562	 subsequently	 fixed	 whereas	 Ova-DQ	 containing	 samples	 were	 incubated	 for	 a	563	 further	 4	 hr	 at	 37°C	 before	 washing	 and	 fixation.	 	 Ova-DQ	 and	 Ova-647	564	 fluorescence	was	enumerated	by	 flow	cytometry.	 	Ova-DQ	 fluorescence	at	4	hr	565	 was	 normalized	 by	 Ova-647	 at	 1	 hr	 to	 allow	 for	 any	 differences	 in	 uptake	 of	566	 reagent.		567	
	568	
Imaging	flow	cytometry	and	flow	cytometry	569	 Cells	were	processed	using	the	Amnis	ImageStreamX	at	60X	magnification	with	570	 the	indicated	excitation	laser,	in	addition	to	the	brightfield	system,	according	to	571	 the	manufacturer’s	instructions.		Amnis	IDEAS	software	was	used	to	analyze	the	572	 data.	 	 The	 IDEAs	 automated	 spot	 counting	 wizard,	 performed	 on	 the	 CD8	573	 expressing	 population,	 was	 used	 to	 determine	 the	 optimal	 spot	 counting	574	 algorithm	 for	 individual	 experiments.	 For	 the	nuclear	 vRNP	 import	 assay,	 spot	575	 counting	was	performed	on	the	“mask”	(region	of	interest)	demarcated	by	DAPI	576	 staining	 using	 a	 threshold	 of	 40%	 of	 the	 maximum	 DAPI	 staining	 intensity.			577	 Standard	 flow	 cytometry	 was	 performed	 using	 the	 FACSCanto	 II	 (BD	578	 Biosciences)	or	the	NovoCyteTM	(Ozyme).	579	 	580	
Co-Immunoprecipitation	and	immunoblot	analysis	581	 U87MG	 cells	 were	 stably	 transduced	 with	 vectors	 carrying	582	 RRL.sin.cPPT.CMV/Flag-NCOA7.WPRE	 or	 RRL.sin.cPPT.CMV/Flag-E2-crimson-583	 .WPRE	 and	 selected	with	 1	µg/ml	 puromycin.	 	 15-22	 x	 106	 cells	were	washed	584	 twice	 in	 cold	PBS	 and	 resuspended	 in	 lysis	 buffer	(20mM	Hepes-NaOH	pH	7.5,	585	 150	 mM	 NaCl,	 1%	NP-40,	 protease	 inhibitor	 cocktail),	 the	 lysates	 clarified	 by	586	 centrifugation	at	1000g,	for	10	min	at	4°C	and	then	incubated	with	Flag-magnetic	587	 beads	 (Life	Technologies)	 for	3	hr	at	4°C.	The	beads	were	washed	5	 times	and	588	 the	 immunoprecipitated	 proteins	 eluted	 using	 3x	 Flag	 peptide	 (150	 μg/ml,	589	 Sigma-Aldrich)	for	1.5-2	hr.	 	Cell	 lysates	and	immunoprecipitation	eluates	were	590	 supplemented	with	sample	buffer	(50	mM	Tris-HCl	pH	6.8,	2%	SDS,	5%	glycerol,	591	 100	mM	DTT,	0.02%	bromphenol	blue),	resolved	by	SDS-PAGE	and	analyzed	by	592	
immunoblotting	using	primary	 antibodies	 specific	 for	 the	 Flag	 epitope	 (Sigma-593	 Aldrich	 F3165),	 tubulin	 (mouse	 monoclonal	 DM1A,	 Sigma-Aldrich	 T9026),	594	 ATP6V1B2	 (Proteintech	 15097-1-AP),	 ATP6V1A	 (Proteintech	 17115-1-AP),	595	 ATP6V1E1	 (Abcam	Ab111733),	ATP6V1G2	 (Proteintech	25316-1-AP),	 followed	596	 by	 secondary	 horseradish	 peroxidase-conjugated	 anti-mouse,	 or	 anti-rabbit	597	 immunoglobulin	 antibodies	 and	 chemiluminescence	 Clarity	 or	 Clarity	 max	598	 substrate	(Bio-Rad).	A	Bio-Rad	ChemiDoc	imager	was	used.		599	 	600	
Statistical	analysis:		601	 Mann	Whitney	 test	 (two-tailed)	was	 used	 for	 statistical	 analysis	 in	 Fig	 1g	 and	602	 Supplementary	Fig	2d.	603	
	604	
Data	availability	605	 The	 datasets	 generated	 during	 and/or	 analyzed	 during	 the	 current	 study	 are	606	 available	from	the	corresponding	authors	on	reasonable	request.	607	 	608	
Figure	legends:	609	
Figure	 1.	 NCOA7	 inhibits	 infection	 by	 viruses	 entering	 through	 the	610	
endocytic	pathway.		 611	 U87MG	 CD4+	 CXCR4+	 cells	 were	 transduced	 with	 EasiLV	 expressing	612	 NCOA7	or	a	 control	 (CD8	or	 luciferase)	and	 treated	with	doxycycline	 for	613	 48	 hr.	 Cells	 were	 challenged	 with	 a)	 VSV-G-pseudotyped	 HIV-1	 based,	614	 GFP-expressing	 lentiviral	 vector	 (VSV-G	 LV)	 or	 HIV-1	 (NL4.3/Nef-IRES-615	 GFP)	or	b)	lentiviral	vectors	pseudotyped	with:	rabies	virus	GP	(RABV-G),	616	
or	amphotropic	MLV	Env	or	RD114	Env.	48	hr	 later,	E2	crimson-positive	617	 cells	 were	 gated	 and	 the	 percentage	 of	 infected,	 GFP-positive	 cells	618	 determined	 by	 flow	 cytometry.	 c)	 A549	 cells	 expressing	 NCOA7	 or	 CD8	619	 were	 infected	with	A/Eng/195/2009,	 fixed	 at	 5	 hr,	 stained	with	 anti-NP	620	 antibody	(green)	and	visualized	by	confocal	microscopy,	and	d)	shows	the	621	 percentage	of	infected	cells	in	c)	as	quantitated	by	ImageJ.	e)	Huh-7.5	cells	622	 were	 transduced	 with	 lentiviral	 vectors	 expressing	 NCOA7	 or	 GFP,	 and	623	 infected	with	 HCV.	 After	 48	 hr,	 cells	 were	 fixed,	 stained	with	 anti-NS5A	624	 antibody	 and	 the	 percentage	 of	 infected	 cells	 was	 determined	 by	 flow	625	 cytometry.	f)	NCOA7	requirement	for	effective	IFNa-induced	inhibition	of	626	 IAV.	 A549-Cas9	 cells	 were	 transduced	with	 lentiviral	 vectors	 expressing	627	 CRISPR	non-targeting	guide	RNAs	(g1/g2-CTRL)	or	guide	RNAs	targeting	628	 IFITM3	or	NCOA7,	singly	or	in	combination.	Cells	were	antibiotic	selected	629	 for	 at	 least	 15	 days,	 seeded	 and	 treated	 for	 24	 hr	 with	 IFNa	 prior	 to	630	 challenge	with	5	x	104	PFU/well	of	IAV	NanoLuc.	The	cells	were	lysed	7	hr	631	 post	 infection	 and	 luciferase	 activity	 measured.	 Relative	 luminescence	632	 results	for	IFNa-treated	and	untreated	conditions	are	shown.		g)	Statistical	633	 analysis	of	 infectivity	 in	 the	absence	 (-)	or	presence	 (+)	of	 IFNa	 from	(f)	634	 combining	different	guides	 from	control	 (n=8),	NCOA7	knock-out	 (n=12)	635	 and	NCOA7/IFITM3	double	knock-out	(n=12)	cell	populations,	****p-value	636	 (95%	 Confidence	 Interval)	 was	 6.351e-05	 (2.2-5.3),	 1.588e-05	 (4.3-6.3)	637	 and	4.955e-05	(0.8-2.9)	for	Dbl	Neg	Ctrl	vs	NCOA7/Neg	Ctrl,	Dbl	Neg	Ctrl	638	 vs	 NCOA7/IFITM3	 and	 NCOA7/Neg	 Ctrl	 vs	 NCOA7/IFITM3	 respectively.	639	
Mann	 Whitney	 test,	 unadjusted,	 two-sided.	 Charts	 show	 the	 mean	 of	 3	640	 independent	 experiments	 for	 a),	 b),	 d)	 and	 e)	 and	 4	 for	 f).	 Error	 bars	641	 indicate	one	standard	deviation	from	the	mean.	642	 	643	
	644	
Figure	2.		NCOA7	function	inhibits	IAV	membrane	fusion. 645	
a)	 Images	from	HA-acidification,	IAV	membrane	fusion	and	nuclear	vRNP	646	 import	assays	performed	by	 imaging	 flow	cytometry	are	 shown.		For	 the	647	 acidification	assay,	A549	cells	expressing	NCOA7	or	CD8,	or	treated	for	1	648	 hr	with	 bafilomycin	A1,	were	 challenged	with	A/Victoria/3/75	 in	 serum	649	 free	medium.	At	1	hr,	 cells	were	 fixed,	 and	stained	with	 the	A1	antibody	650	 that	 recognizes	 the	acidified	 form	of	HA.	For	 the	 fusion	assay,	 cells	were	651	 challenged	with	 SP-DiOC18-labelled	 A/Victoria/3/75	 and	 fixed	 at	 1.5	 hr	652	 post	 infection.	 The	 control	 virus	 was	 heat-inactivated	 (HI)	 prior	 to	653	 labelling	 and	 infection.	 For	 the	 nuclear	 vRNP	 import	 assay,	 cells	 were	654	 challenged	 with	 A/Eng/195/2009,	 the	 medium	 changed	 at	 1	 and	 3	 hr	655	 while	 maintained	 in	 1	 mM	 cycloheximide.	 Cells	 were	 fixed	 at	 5	 hr	 and	656	 stained	 with	 anti-NP	 antibody;	 nuclei	 were	 demarcated	 with	657	 DAPI.		Acidified	HA	staining,	 fluorescent	SP-DiOC18,	and	nuclear	NP	spot	658	 counts	 were	 quantitated	 by	 imaging	 flow	 cytometry.	 Representative	659	 images	 (from	 3	 independent	 experiments)	 from	 spot	 count	 defined	660	 quintiles	 for	 the	 CD8	 control	 population	 are	 shown	 in	 addition	 to	 the	661	 highest	 quintile	 for	 the	bafilomycin	A1	 and	heat	 inactivation	 (inhibition)	662	
controls.	b-d)	Histograms	 show	 spot	 count	 distributions	 across	 the	 CD8	663	 control	and	NCOA7	populations	(equal	numbers	of	cells	displayed,	>1000	664	 per	 condition)	 from	 a	 representative	 experiment	 for	 each	 assay	 (n=3	665	 independent	experiments).		Populations	are	gated	on	the	upper	quintile	of	666	 the	 CD8	 control,	 with	 the	 bar	 graphs	 indicating	 the	 mean	 relative	667	 proportion	 of	 the	 gated	 populations	 from	 3	 independent	668	 experiments.		Error	bars	represent	one	standard	deviation	from	the	mean. 669	 	670	 	671	
Figure	 3.	 NCOA7	 interacts	 with	 the	 V-ATPase	 and	 promotes	672	
cytoplasmic	vesicle	acidification	and	lysosomal	protease	activation. 673	
a)	 U87MG	 cells	 were	 transduced	 with	 lentiviral	 vectors	 constitutively	674	 expressing	Flag-tagged	E2-crimson	(E2)	or	NCOA7.		Cells	were	 lysed,	and	675	 the	Flag-tagged	proteins	recovered	by	immunoprecipitation	and	analyzed	676	 by	 immunoblotting	 using	 anti-tubulin	 (loading	 control),	 anti-Flag,	 anti-677	 ATP6V1B2,	 anti-ATP6V1A,	 anti-ATP6V1E	 or	 anti-ATP6V1G2	 antibodies.	678	 CL,	 whole	 cell	 lysate;	 IP,	 immunoprecipitate.	 One	 representative	679	 immunoblot	 from	 3	 independent	 experiments	 is	 shown.	 b)	 A549	 cells	680	 expressing	 NCOA7	 or	 CD8	 were	 plated	 on	 glass-bottomed	 dishes	 and	681	 treated	 for	 1	 hr	with	 1	mM	 LysoSensor	 Green.		 Cells	were	 subsequently	682	 washed,	incubated	in	clear	medium	and	were	visualized	(live)	by	confocal	683	 microscopy.	 	Representative	images	from	3	independent	experiments	are	684	 shown.	 c)	 A549	 cells	 (as	 in	 panel	 b)	 were	 seeded,	 treated	 with	 0.1	 µM	685	
LysoSensor	 Green	 DND-189	 for	 1	 hr,	 or	 with	 10	 µM	 Lysosensor	686	 Yellow/Blue	 DND-160	 for	 30	 min,	 trypsinized	 and	 washed.	 	 For	687	 LysoSensor	 Green,	 fluorescent	 spot	 counts	 were	 determined	 by	 imaging	688	 flow	cytometry	and	 the	data	are	 represented	as	 in	Fig	2.	For	Lysosensor	689	 Yellow/Blue	 the	 ratio	 of	 the	 mean	 fluorescence	 intensity	 of	 the	 cells	 in	690	 channels	 420-505	 nm	 and	 505-570	 nm	 was	 measured	 for	 the	 analysis	691	 (>2,000	 cells	 per	 condition)	 d)	 Arranged	 as	 in	 c)	 but	 the	 cells	 were	692	 trypsinized	prior	to	treatment	with	Magic	Red	cathepsin	B,	L	or	K	reagents	693	 for	 1.5	 hr.		 Cells	 were	 fixed	 and	 analyzed	 by	 imaging	 flow	 cytometry	694	 (>3,000	cells	per	condition	are	displayed).			 e)	Arranged	as	in	c)	but	cells	695	 were	 incubated	 in	 serum-free	 media	 containing	 250	 μg/ml	 of	 DQ	696	 Ovalbumin	 (Ova-DQ)	 or	 Alexa	 Fluor	 647	 Ovalbumin	 (Ova-647)	 for	 1	 hr	697	 followed	 by	washing.	 	 Ova-647	 containing	 cells	were	 subsequently	 fixed	698	 whereas	 Ova-DQ	 containing	 samples	 were	 incubated	 for	 a	 further	 4	 hr	699	 before	 washing	 and	 fixation.	 	 Ova-DQ	 fluorescence	 was	 enumerated	 by	700	 flow	cytometry	and	Ova-647	was	used	to	normalize	for	uptake.	The	mean	701	 of	3	independent	experiments	is	shown	with	error	bars	representing	one	702	 standard	deviation	from	the	mean.		703	 	704	
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